Skip to main content
Apellis Pharmaceuticals, Inc. (APLS)
May 14, 2026 - APLS was delisted (reason: acquired by BIIB)
41.03
-0.03 (-0.07%)
Inactive · Last trade price on May 13, 2026

Apellis Pharmaceuticals Revenue by Segment
Period Ending Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021
Product
689.38M 690.21M 689.03M 696.78M 709.95M 657.44M 580.05M 490.56M
Product Growth
-2.90% 4.99% 18.79% 42.04% 93.83% 165.87% 249.90% 434.47%
Collaboration License and Other
314.40M 326.18M 65.62M 79.06M 71.41M 57.78M 48.74M 33.51M
Collaboration License and Other Growth
340.25% 464.53% 34.64% 135.91% 135.62% 125.73% 159.80% 137.61%

Product Revenue by Segment
Period Ending Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021
Syfovre
587.00M 599.55M 600.59M 604.58M 611.85M 558.35M 481.67M 394.39M
Syfovre Growth
-4.06% 7.38% 24.69% 53.30% 122.26% 246.84% 462.03% 2,048.08%
Empaveli
102.00M 90.69M 88.47M 92.22M 98.13M 99.13M 98.42M 96.21M
Empaveli Growth
3.94% -8.52% -10.11% -4.15% 7.79% 14.81% 22.81% 30.91%
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.